Abstract
P2.03a-018 A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have